ARTICLE | Company News

Pfizer, Kyowa Hakko Kirin deal

October 6, 2014 7:00 AM UTC

Pfizer and Kyowa will co-fund a Phase Ib trial of Pfizer's PF-05082566 plus Kyowa's Poteligeo mogamulizumab to treat solid tumors. Pfizer will conduct the U.S. trial, which is expected to start next year. Pfizer said financial terms are not disclosed.

PF-05082566 is a mAb agonist of tumor necrosis factor (TNF) receptor superfamily member 9 ( TNFRSF9; 4-1BB; CD137) that is in Phase I testing for multiple tumor types. Poteligeo, a humanized mAb against CC chemokine receptor 4 (CCR4; CD194), is approved in Japan to treat the following CCR4-positive cancers: T cell leukemia-lymphoma, relapsed or refractory peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL). ...